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Article abstract—Objective: To analyze the MRI and CSF oligoclonal bands (OB) changes in patients with MS who
underwent an autologous hematopoietic stem cell transplantation (AHSCT). Background: AHSCT is evaluated as an
alternative therapy in severe MS. In previous series of AHSCT for MS, data on MRI or OB outcome were limited or not
provided. Methods: Five patients with a median Kurtzke’s EDSS score of 6.5, more than two attacks, and confirmed
worsening of the EDSS in the previous year received an AHSCT. Hematopoietic stem cells were mobilized with cyclophos-
phamide (3 g/m2) and granulocyte colony-stimulating factor (5 mg/kg/d). The graft was T cell depleted by positive CD 341
selection. Conditioning regimen included BCNU (300 mg/m2), cyclophosphamide (150 mg/kg in 3 days), and antithymocyte
globulin (60 mg/kg in 4 days). MRI scans were scheduled at baseline and 1, 3, 6, and 12 months and OB analysis at
baseline and 3 and 12 months post-AHSCT. Results: Four patients had a stable or improved EDSS after a median
follow-up of 18 months (range, 12 to 24 months). The fifth patient’s condition deteriorated during AHSCT. She partially
improved and remained stable after month 3 after AHSCT. The baseline CSF OB persisted 1 year after AHSCT. MRI
studies after AHSCT showed no enhanced T1 lesions and no new or enlarging T2 lesions. The median percentage change
of T2 lesion load was 211.8% (range, 226.6 to 24.0%). All patients had a decrease of corpus callosum area at 1 year
(median, 12.4%; range, 7.8% to 20.5%) that did not progress in the two patients evaluated at 2 years after AHSCT.
Conclusions: Although the persistence of CSF OB suggests the lymphocytes were not eliminated from the CNS, the
follow-up MRI studies showed no enhanced T1 brain lesions and a reduction in the T2 lesion load that correlated with the
clinical stabilization of MS after AHSCT.
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Immune ablation with autologous hematopoietic
stem cell transplantation (AHSCT) is evaluated as a
potential treatment for severe cases of MS and other
systemic autoimmune diseases.1,2 The rationale for
using AHSCT to treat MS is based on isolated MS
case reports of patients who underwent this treat-
ment for a concomitant hematologic malignancy and
the positive effect of syngeneic or autologous bone
marrow transplantation on the prevention or remis-
sion of experimental allergic encephalomyelitis.3 The
aim of AHSCT is to produce a profound T-cell deple-
tion and to reconstitute an immune system with a
new immune tolerance. Although this objective
would be better accomplished by use of an allogeneic
hematopoietic stem cell transplantation, the morbid-
ity and mortality of this type of transplantation pre-
vents its use in patients with MS.
Few studies of AHSCT in MS have been pub-
lished.4–7 They addressed the feasibility of the proce-
dure, but no detailed information was provided on
the evolution of the MRI lesions or the CSF abnor-
malities that would help in the understanding of the
effects of the AHSCT. We describe the clinical, MRI,
and CSF evolution of the first five patients with MS
receiving an AHSCT at our institution, after a me-
dian follow-up of 18 months.
Methods. Patients. The patients reported are the first
five included in a prospective protocol to evaluate the
safety of T cell–depleted AHSCT for patients with severe
MS. The treatment protocol is described in the Appendix.
Eligibility criteria include: 1) age between 18 and 60 years;
2) clinically definite secondary progressive (SPMS) or re-
lapsing remitting (RRMS) with a Kurtzke’s Expanded Dis-
ability Status Scale (EDSS) of 4.0 to 6.5; 3) an increase in
the EDSS by 1.0 point with an EDSS of 5.5 or less or 0.5
with an EDSS .5.5 over the previous year in spite of
treatment with interferon or other immunotherapies that
are stopped at least 1 month before the AHSCT. Patients
with RRMS must have at least two relapses in the last
year. Patients are excluded if there is significant history of
medical illness precluding transplantation, cognitive dete-
rioration, or severe atrophy seen in the brain MRI. The
protocol is approved and monitored by the ethical and re-
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search committees of the institution and the Spanish Min-
istry of Health.
Clinical evaluation. The neurologic status of the pa-
tients was evaluated (neurologic examination, EDSS, Am-
bulatory Index [AI] score) at baseline, at the end of stem
cell mobilization, at months 1, 3, 6, 9, and 12 after AHSCT,
and then every 6 months. Hematologic follow-up after hos-
pital discharge and schedule of immunizations after treat-
ment were done according to guidelines previously
reported.8 Systemic adverse effects were scored by using
the Bearman’s scale.9
MRI evaluation. Brain MRI scans were obtained be-
fore the stem cell mobilization (baseline) and months 1, 3,
6, and 12 after AHSCT with a 1.5-T unit Siemens Magne-
tom SP (Erlangen, Germany) with a quadrature head coil.
Two-dimensional gradient-echo scout images, acquired in
three planes, were used for positioning slices in the MRI
procedure. Sections with a thickness of 5 mm were ac-
quired in the axial plane (parallel to the body of the corpus
callosum) by using the following parameters: minimal in-
terslice gap (,1 mm) and 192 3 256 matrix.
The MRI protocol consisted of sagittal spin-echo T1-
weighted images (repetition time [TR], 608 msec; echo time
[TE], 14 msec), axial spin-echo T1-weighted images (TR/TE
608/14), and sagittal fast spin-echo T2-weighted images
(TR/TE 4600/90). Axial spin-echo T2-weighted images in-
cluded proton density (TR/TE 2500/15) and T2 (TR/TE
2500/90). All T1-weighted images also were acquired 5
minutes after IV injection of 0.1 mmol/kg gadodiamide
(Omniscan; Nycomed, Inc, Princeton, NJ).
A single experienced neuroradiologist (J.B.) visually
identified and counted the number of hypointense and en-
hanced lesions in precontrast and postcontrast T1-
weighted images and hyperintense lesions in T2-weighted
images. The measurement of lesion volume by using T2
sequences of the baseline and 1 year post-AHSCT MRI was
calculated with a workstation Sienet DRC 104 (Siemens,
Erlangen, Germany). Lesion volume calculations were ob-
tained by using manual tracking, based on the lesional
volume obtained by multiplying the total hyperintense le-
sion area by the thickness of the section and summation of
the value of each section. The atrophy measures were
based on the precontrast axial (lateral ventricle and brain
widths) and sagittal (corpus callosum area) T1-weighted
images and calculated in the workstation monitor.10 The
mean coefficients of variation, obtained as described,10
were 1.5%, 0.3%, and 5% for ventricle width, brain width,
and corpus callosum area. All studies were done blind to
the clinical evolution of the patients.
CSF analysis. Paired serum/CSF samples were ob-
tained at baseline and 3 and 12 months after AHSCT and
stored at 280 °C. Integrity of the blood–brain barrier
(BBB) was estimated by the albumin index (upper normal
value, 9.0). The identification of IgG-specific oligoclonal
bands (OB) in CSF and serum was performed with an
IgG-IEF Kit (Helena BioScience, Sunderland, UK) accord-
ing to manufacturer’s instructions. Basically, paired se-
rum/CSF samples were run in an agarose gel isoelectric
focusing, pH 3–10. The separated proteins were trans-
ferred to a nitrocellulose membrane, immunofixed with
sheep anti-human IgG peroxidase conjugated, and devel-
oped with 3-amino-9 ethylcarbazole (Sigma, St. Louis,
MO). The patterns were interpreted qualitatively by com-
paring the presence or absence of oligoclonal bands in CSF
or serum.
Hematologic and immune evaluation. Peripheral blood
was examined at baseline and months 3, 9, and 12 after trans-
plantation, and then every 6 months. T cells (CD31), helper/
inducer T cells (CD31CD41), naive (CD41CD45RA1) and
memory (CD41CD45RO) helper/inducer T cells, suppressor/
cytotoxic T cells (CD31CD81), and B cells (CD191) were
analyzed on a FACScan (Becton Dickinson Immunocytom-
etry Systems [BDIS], San Jose, CA).11
Results. Baseline patient characteristics. The five pa-
tients had a mean disease duration of 9 years (range, 6
to14 years). Two patients had RRMS and three had SPMS.
The median scores of EDSS was 6.5 (range, 5.0 to 6.5), and
that of AI, 4 (range, 2 to 6). Both patients with RRMS had
six relapses the previous year despite treatment with in-
terferon b and repeated boluses of IV methylprednisolone
(table 1).
Toxicity. There were no major systemic complications
(table 1). Patient 5 presented an exacerbation of her leg
weakness while receiving granulocyte colony-stimulating
factor (G-CSF), which returned to baseline in a few days.
Patient 2 developed a severe paraparesis concomitant with
high fever associated with the administration of antithy-
mocyte globulin (ATG), and her EDSS score increased from
6.5 to 8.0. She slowly improved to an EDSS of 7.5 over the
ensuing 3 months. Four patients had uncomplicated uri-
nary tract infections during the first 3 months after hospi-
tal discharge. Menstruation did not return in the oldest
woman.
Neurologic outcome. At the last evaluation (median
follow-up, 18 months; range, 12 to 24 months), the EDSS
improved in Patients 4 (from 6.5 to 5.0) and 5 (from 6.5 to
5.5), was unchanged in Patients 1 and 3, and remained
stable after month 3 after AHSCT in Patient 2, whose
condition worsened during the transplantation. Patient 3
had two relapses and Patient 4 one after AHSCT. All the
episodes were subjective sensory symptoms that lasted a
few days and did not require treatment. The neurologic
examination during the relapse did not disclose any new
sign, but the distribution of the sensory symptoms sug-
gested an involvement of the spinal cord. Fatigue (al-
though not formally measured) and urinary symptoms
(once urinary infections were controlled) improved along
the follow-up period in the five patients. None of the pa-
tients needed additional immunotherapy after AHSCT.
MRI evaluation. The baseline MRI characteristics are
shown in table 2. Enhanced T1 lesions were presented in
Patients 1, 3, and 5 and disappeared in the MRI done 1
month after AHSCT. The follow-up MRI studies did not
show enhanced T1 lesions and no new hypointense T1
lesions, except in one patient who had a new hypointense
lesion that corresponded to an enhancing lesion at baseline
MRI. No new or enlarging hyperintense lesions on T2-
weighted images were observed at the follow-up MRI stud-
ies in the five patients. The median percentage change of
T2 lesion volume was 211.8% (range, 226.6 to 24.0%)
(table 2).
A decrease in the corpus callosum area was observed in
the five patients at 1 year (median decrease, 12.4%; range,
7.8% to 20.5%). The atrophy was independently confirmed
by another neuroradiologist, with an interobserver median
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variation in the percentage of the atrophy of the corpus
callosum of 1.2% (range, 0.1% to 3.9%). More than 50% of
the reduction of the corpus callosum area occurred in the
first 3 months after AHSCT in all of the patients. The
percentage of loss during this period was 82% in Patient 2
and 80% in Patient 5. The MRI 2 years after AHSCT done
in Patients 1 and 2 showed no new enhanced or hypoin-
tense T1 lesions, a further reduction of the T2 lesion load,
and the arrest in the decrease of the corpus callosum area
seen during the first year after transplantation.
CSF evaluation. All patients showed OB in the base-
line CSF examination. Patient 4 refused further lumbar
punctures. At month 3 after AHSCT, Patients 1, 3, and 5
developed multiple OB in the serum, and many of them
were also present in the CSF. Some of the observed OB in
the baseline CSF were also identified in the serum. The
intensity of these OB was stronger in the CSF than in the
serum in Patients 1 and 5 (figure) and identical in Patient
3. The albumin index suggested a disruption of the BBB in
the three patients (albumin index, 9.4, 14.8, and 20.1).
Patient 2 did not present OB in the serum or disruption of
the BBB at 3 months after AHSCT. At 1 year, the four
patients (1, 2, 3, and 5) had the same CSF OB identified in
the baseline CSF. In addition, some of the serum OB of
Patients 1, 3, and 5, that appeared at month 3 persisted
and were also identified in the CSF (figure).
Immune reconstitution after transplantation. All pa-
tients had a total number of peripheral blood lymphocytes
.500/mL and normal values of CD8 1 T cells at 3 months
after transplantation. CD41 T cells achieved cell counts
higher than 200/mL at 12 months after transplant in four
of five patients. Throughout the period of the study, almost
all CD41 lymphocytes expressed CD45RO antigen (memo-
ry T cells), and only low numbers of cells expressed
CD45RA antigen (naive T cells). All of the patients had
normal values of B-lymphocytes at 9 months after
treatment.
Discussion. AHSCT is an experimental treatment
option for severe forms of MS. The efficacy of AHSCT
remains to be demonstrated, and this treatment
should be considered only in the setting of approved
protocols. This study confirms previous work that
patients with severe MS tolerate AHSCT with ac-
ceptable toxicity4-7 and shows for the first time three
features that may be relevant for future studies.
First, IgG OB in the CSF did not disappear after
AHSCT; second, follow-up MRI showed a decrease in
T2-weighted lesion load that persisted in absence of
additional immunotherapy; and third, there was a
decrease in corpus callosum area in spite of an ab-
Table 1 Baseline clinical characteristics, number of reinfused cells, hematologic recovery, and toxicity of the treatment
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age, y/sex 30/F 43/F 24/F 44/M 27/F
MS type SP SP RR SP RR
Baseline evaluation
EDSS 6.0 6.5 5.0 6.5 6.5
Ambulation index 4 6 2 4 4
Number of relapses 3 2 6 2 6
Number of reinfused cells
CD341 (3 106/kg) 7.6 3.4 4.7 2.5 4.8
CD31 (3 104/kg) 30 7 0.27 0.64 0.29
Engraftment, d
Neutrophils .500/mL 19 111 111 112 19
Platelets .20,000/mL 111 114 112 115 112
Toxicity
Mucositis* Yes Yes Yes Yes Yes
Fever Yes Yes Yes Yes Yes
Documented infection — S aureus — S epidermidis S epidermidis
E coli CMV†
Neurologic deterioration No Yes‡ No No Yes§
Other toxicities (grade) No No No No Hepatic (II)¶
Days in hospital 18 29 35 21 46
* Grade I 5 mucositis not requiring continuous IV analgesia.
† Asymptomatic reinfection.
‡ During conditioning, incomplete recovery.
§ During mobilization, complete recovery.
¶ Grade II 5 AST/ALT .5 times of normal values.
SP 5 secondary progressive MS; RR 5 relapsing-remitting MS; EDSS 5 Expanded Disability Status Scale score.
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sence of inflammatory disease activity during the
first year after AHSCT.
AHSCT was not associated with severe systemic
toxicity. However, one of the patients presented a
severe neurologic deterioration during the treatment
that did not recover to the baseline level. Transient
neurologic worsening is described in up to 42% of
patients during the procedure,7 but our patient em-
phasizes that this complication may be only partially
reversible. Another patient had a transient neuro-
logic deterioration while receiving granulocyte
colony-stimulating factor (G-CSF) for stem cell mobi-
lization. This patient had multiple relapses in the
year previous to the transplantation and the possi-
bility of a coincidence with the G-CSF treatment can-
not be excluded. The mechanism of this complication
is uncertain but has been reported, particularly
when G-CSF alone is used to mobilize stem cell to
the periphery.12 The current protocol uses half of the
recommended dose of G-CSF1,2 with a priming dose
of cyclophosphamide that may counteract possible
immunostimulatory effects of G-CSF. We have not
observed this complication in the subsequent six pa-
tients who have been treated with this protocol
(unpublished).
The five patients’ conditions remained neurologi-
cally stable or improved after discharge from the
hospital. The absence of T1-enhancing lesions and
the lack of new or enlarging hyperintense T2 lesions
in the follow-up MRI suggests that AHSCT had a
positive impact on active inflammation13 and seems
to agree with the clinical stabilization of our patients
in the first year after AHSCT.14 However, these MRI
features are not a good predictor of long-term dis-
ability, and only the follow-up will unambiguously
show whether the treatment has been able to modify
the clinical course of these patients.
All patients showed an increase in the atrophy of
the corpus callosum in spite of improvement of the
other MRI variables. The relationship between in-
flammatory activity and the development of brain
atrophy is unclear. In longitudinal studies of brain
Figure. Identification of immunoglobulin G–specific oligo-
clonal bands (OB) from Patient 5. The baseline CSF had
at least three OB (open triangles). These bands persisted
at month 3 after transplantation, and they were also seen
in the serum but with a weaker intensity. At month 12, the
three bands were only observed in the CSF. Serum at
month 3 showed multiple OB (closed triangles) that were
also present in the CSF. Some of these bands were still
present in the serum and CSF 12 months after treatment.
SO/CO 5 Baseline serum/CSF; S3/C3 5 serum/CSF 3
months after transplantation; S12/C12 5 serum/CSF 12
months after transplantation.
Table 2 MRI outcomes after autologous hematopoietic stem cell transplantation
Outcomes Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Baseline
Mean T2 lesion volume, cm3 19.32 31.48 37.57 2.89 3.08
Enhanced T1 lesions 12 0 5 0 6
Hypointense T1 lesions* 22 18 22 5 2
Atrophy variables
Lateral ventricle width, mm 29 24 24 33 16
Brain width, mm 86 92 87 94 95
Corpus callosum area, mm2 685 523 461 594 515
1 Year after transplantation
Percentage change of mean lesional volume from baseline 219.7 226.6 210.3 24.0 211.8
Enhanced T1 lesions 0 0 0 0 0
Hypointense T1 lesions 22 18 22 5 3
Percentage change of atrophy from baseline
Lateral ventricle width 0 0 117.2 113.5 0
Brain width 24.6 0 23.4 0 0
Corpus callosum area 27.8 214.9 211.7 212.4 220.5
* All lesions less than 1.3 mm.
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atrophy in untreated patients with RRMS, the de-
crease in corpus callosum area appears to be influ-
enced by the baseline number of gadolinium-
enhancing lesions.10 However, similar studies that
used volumetric techniques failed to show a correla-
tion of brain atrophy with enhanced lesion load.15
Taken these data together, one cannot rule out that
the AHSCT could be effective in arresting the in-
flammatory activity but fail to reverse the pathologic
process responsible for the brain atrophy. A second
explanation is that the atrophy could be caused, at
least in part, by the AHSCT. More than 50% of the
atrophy occurred in the 3 months after AHSCT, par-
ticularly in the two patients who had a more compli-
cated AHSCT. This possibility would be further
supported by the observation that the atrophy of the
corpus callosum did not increase during the second
year after the treatment. Brain atrophy was ob-
served in patients undergoing allogeneic bone mar-
row transplantation for chronic myeloid leukemia,16
but specific measurements of the corpus callosum
area were not provided. If the brain atrophy found in
our patients is related to the treatment, this effect
could be more evident in transplantation protocols
that include total body radiation1,2 because of the
potential synergistic effect of chemotherapy and ra-
diation therapy in causing neurotoxicity.17
The CSF analysis 3 months after AHSCT showed
a disruption of the BBB and the presence of many
OB that were also identified in the serum. Serum OB
was reported in up to 87% of patients who had an
AHSCT for multiple myeloma and persisted 7
months on the average.18,19 The significance of these
serum OB is unclear, but they could reflect recapitu-
lation of early B-cell ontogeny. Persistence of CSF
OB at 1 year after AHSCT was previously observed
in two patients who were treated with busulfan, cy-
clophosphamide, and antithymocyte globulin.20 The
serial analysis of the CSF OB at 3 and 12 months
after AHSCT in our patients supports the idea that
the B cells responsible for the IgG synthesis in the
CNS survived the conditioning regimen. Unlike
other CSF OB detected at 3 months after transplan-
tation, at least some of the OB seen at the baseline
CSF showed a stronger intensity in the CSF than in
the serum. This observation suggests the B cells re-
sponsible for its synthesis were in the CNS, and the
OB diffused to the serum because of the disruption of
the BBB.
Unlike other published AHSCT protocols,4-7 we did
not include in the conditioning regimen total body
irradiation or added other drugs, as melphalan, eto-
poside, or cytosine arabinoside that in theory could
be more effective to eradicate the lymphocytes in the
CNS. We decided not to use these approaches for the
concern of an increased incidence of cancer later in
life.21-23 In addition, there is clinical24 and experimen-
tal25 evidence of neurologic deterioration after use of
brain irradiation on demyelinating lesions.
The clinical impact of the presumable persistence
of the lymphocytes in the CNS is unclear because the
MRIs did not show features compatible with disease
activity, and the EDSS did not increase after hospi-
tal discharge. However, the evolution of CSF OB and
the brain atrophy should be recorded in transplanta-




Mobilization of hematopoietic stem cells: Cyclophosphamide 3
g/m2 1 granulocyte colony-stimulating factor (G-CSF) (5 mg/kg/d)
Peripheral blood stem-cell collection: Fenwal CS3000 (Baxter)
Leukapheresis: One T-cell–depleted 1 one non–T-cell–depleted
(backup) (target in both: 3 3 106 CD341/kg)
Positive CD341 selection: Isolex 300 (Baxter) (Patients 1, 2)
CliniMACS (Miltényi) (Patients 3–5)
Conditioning regimen:
Day 26—BCNU (300 mg/m2)
Day 25—Antithymocyte globulin (Merieux) (ATG) (15 mg/kg),
cyclophosphamide (50 mg/kg)
Day 24—ATG (15 mg/kg), cyclophosphamide (50 mg/kg)
Day 23—ATG (15 mg/kg), cyclophosphamide (50 mg/kg)
Day 22—ATG (15 mg/kg)
Day 21—Rest
Day 0—Hematopoietic stem cell transplantation
Supportive care: Laminar airflow room; low microbial diet; oral
ciprofloxacin, fluconazole, and acyclovir; inhaled pentamidine;
IVIg, G-CSF (day 11), and ganciclovir if positive cytomegalovirus
antigenemia
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The influence of cognitive impairment on
driving performance in multiple sclerosis
Maria T. Schultheis, PhD; Edward Garay, BS; and John DeLuca, PhD
Article abstract—Objective: To examine the influence of impaired cognitive processing on measures of driving skills in
persons with MS. Methods: Twenty-eight subjects with documented MS were divided into two groups—with [MS(1), n 5
13] and without [MS(2), n 5 15] cognitive impairment—based on neuropsychological performance. Healthy control (HC)
subjects (n 5 17) matched on age and driving experience were also studied. Driving-related skills were compared between
the groups based on performance on two computerized driving tests: the Useful Field of Vision (UFOV) and the Neurocog-
nitive Driving Test (NDT). Results: The MS(1) group performed significantly worse than both the MS(2) and HC groups
in the latency to perform several driving-specific functions on the NDT, but no overall group differences were observed in
actual errors on the NDT. On the UFOV, when compared to MS(2) and HC subjects, the MS(1) group demonstrated
poorer performance on two of the three subtests. Additionally, a significantly higher percentage of MS(1) individuals were
rated within the high risk (probability of crash involvement) category, relative to the MS(2) and HC groups. Conclusions:
Cognitive impairment can negatively affect driving-related skills in persons with MS and should be considered in the
determination of driving ability.
NEUROLOGY 2001;56:1089–1094
The impact of cognitive impairment on driving skills
and abilities has been documented in various neuro-
logic populations, including brain injury,1-3 stroke,4,5
and dementia.6,7 These studies have identified de-
creased attentional and visual perceptual skills,
slowed information processing speed, and executive
dysfunction as related to impaired driving skills and
abilities.8-11 Despite recent evidence indicating the
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